Finance

Beta
Lists
PASG:NASDAQ
Passage Bio Inc
$4.70
+8.55%
(+0.37) 1D
$4.56
-2.94% (-0.14)
After hours
Closed: Jun 26, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PASG...
Open
$4.30
High
$5.00
Low
$4.19
Mkt. cap
15.10M
Avg. vol.
100.94K
Volume
280.49K
52-wk high
$20.00
52-wk low
$3.29
EPS
-$11.84
Beta
1.41
Shares outstanding
3.21M
No. of employees
24
Open
$4.30
High
$5.00
Low
$4.19
Mkt. cap
15.10M
Avg. vol.
100.94K
Volume
280.49K
52-wk high
$20.00
52-wk low
$3.29
EPS
-$11.84
Beta
1.41
Shares outstanding
3.21M
No. of employees
24
News stories
From sources across the web
About Passage Bio Inc
CEO-
Employees24
Founded2017
HeadquartersPhiladelphia, Pennsylvania, United States
SectorBiotechnology
Websitepassagebio.com
Analyst ratings
Based on 6 analysts giving stock ratings to PASG in the past 3 months
Hold
Buy
1
Hold
5
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for PASG in the last 3 months.
Highest
Current $4.70
$23.00 (+389.36%)
Average
$11.75 (+150.00%)
Lowest
$7.00 (+48.94%)
Analyst
Recommendation
Action
Price target
Projected
Date
Debjit Chattopadhyay
Guggenheim
Hold
Downgraded
-
-
06/10/2026
Brendan Smith
TD Cowen
Hold
Reiterated
-
-
05/12/2026
Yaron Werber
TD Cowen
Hold
Downgraded
-
-
04/21/2026
Jay Olson
Oppenheimer
Buy
Reiterated
$15.00
+219.1%
04/21/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$23.00
+389.4%
04/21/2026
Janani Sundararajan
Chardan Capital
Hold
Downgraded
$7.00
+48.9%
04/20/2026
Yun Zhong
Wedbush
Hold
Downgraded
$8.00
+70.2%
04/21/2026
Elemer Piros
Lucid Capital
Hold
Downgraded
$9.00
+91.5%
04/20/2026
Last report
May 12, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$2.36 / -$3.01
+21.66%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
5.81M
4.31M
5.42M
4.09M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.52M
4.35M
4.92M
4.79M
Operating expense
10.33M
8.66M
10.34M
8.88M
Total operating expenses
10.33M
8.66M
10.34M
8.88M
Operating income
-10.33M
-8.66M
-10.34M
-8.88M
Other non operating income
-451.00K
406.00K
365.00K
388.00K
EBT including unusual items
-9.38M
-7.75M
-12.98M
-7.56M
EBT excluding unusual items
-9.38M
-7.75M
-9.48M
-8.19M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-9.38M
-7.75M
-12.98M
-7.56M
Net profit margin
-
-
-
-
Earnings per share
-2.96
-2.44
-4.09
-2.36
Interest and investment income
1.40M
500.00K
500.00K
300.00K
Interest expense
-
-
-
-
Net interest expenses
1.40M
500.00K
500.00K
300.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.16M
-8.47M
-10.16M
-8.75M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of PASG
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer